Text Size

Effect of Niacin ER/Lovastatin on Peak Walking Time & Claudication Onset Time in Patients With Intermittent Claudication

This study has been completed.
Sponsor:
Information provided by:
Kos Pharmaceuticals
ClinicalTrials.gov Identifier:
NCT00062556
First received: June 9, 2003
Last updated: October 31, 2006
Last verified: October 2006
History of Changes
  Purpose

The purpose of this study is to evaluate if Niacin ER/Lovastatin, at two different doses, compared to diet control (this group will receive a tablet containing 50 mg. of immediate-release niacin) is a safe and effective medicine in subjects with leg pain caused by a narrowing of their leg arteries, a condition called intermittent claudication.

At least 366 subjects with leg pain caused by a narrowing of their leg arteries will participate in this study.

Niacin ER/Lovastatin is a combination of two FDA (United States Food and Drug Administration) approved cholesterol modifying medications: Niaspan® (extended-release niacin) and lovastatin, a statin (the same medicine found in Mevacor®). Niacin ER/Lovastatin was approved by the FDA under the name of Advicor® for use in the treatment of elevated cholesterol. The use of Niacin ER/Lovastatin in the treatment of peripheral arterial disease and symptomatic relief of intermittent claudication is considered investigational. An investigational use is one that is not approved by the FDA.


Condition Intervention Phase
Intermittent Claudication
Peripheral Vascular Disease
 Drug: Niacin Extended Release and Lovastatin Tablets
 Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: Effect of Niacin ER/Lovastatin on Peak Walking Time and Claudication Onset Time in Patients With Intermittent Claudication

Resource links provided by NLM:

U.S. FDA Resources

Further study details as provided by Kos Pharmaceuticals:

Estimated Enrollment: 366
Study Start Date: January 2003
Estimated Study Completion Date: March 2006
Detailed Description:

This is a Phase 3, 28-week, double-blind, diet-intervention, randomized, parallel group, three-arm, multi-center, dose-titration study.

The objectives of this study are to evaluate the safety and efficacy of NL in patients with IC. The primary efficacy analysis will be the percent change from baseline in Peak Walking Time (PWT) and Claudication Onset Time (COT), calculated as the logarithm of the quotient of the time walked on treadmill at a visit divided by the time walked at baseline. Other efficacy measures will include Ankle Brachial Index (ABI), QoL measurements, composite of cardiovascular events (MI, stroke, vascular death, and lower limb amputations), and coronary and peripheral artery revascularization procedures. Safety variables will include serum transaminases, routine chemistry parameters, hematology, and AEs. Pharmacokinetic analyses will be conducted as well.

  Eligibility

Ages Eligible for Study:   40 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

INCLUSION CRITERIA:

  • Men & women at least 40 years of age or older. Women must not be pregnant nor breast-feeding & not planning to become pregnant or to breast-feed.
  • History of IC of the lower extremities which has been present for at least 6 months with no change in symptoms in the previous 3 months prior to screening.
  • LDL-C of < 160 mg/dL and Triglycerides < 800mg/dL.

EXCLUSION CRITERIA:

  • Severe neuropathy
  • Gross obesity (BMI ≥ 40)
  • Presence of critical limb ischemia defined as ischemic rest pain, gangrene, ulceration, or pending amputation of a lower extremity due to severe PAD.
  • Surgical intervention to alleviate symptoms of claudication within 6 months or endovascular interventions within 3 months
  • Documented CAD taking any cholesterol-modifying agent
  • Systolic blood pressure ≥ 160 mmHg &/or diastolic blood pressure ≥ 95 mmHg
  • Presence of clinically significant laboratory test abnormalities for liver or renal function tests or HgbA1C.
  • History of alcohol abuse or currently drinks alcohol in excess.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

No publications provided by Kos Pharmaceuticals

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):

ClinicalTrials.gov Identifier: NCT00062556     History of Changes
Other Study ID Numbers: MA-02-010403, ICPOP
Study First Received: June 9, 2003
Last Updated: October 31, 2006
Health Authority: United States: Food and Drug Administration

Keywords provided by Kos Pharmaceuticals:
Intermittent Claudication
Peripheral Arterial Disease
Atherosclerosis
Niacin
 Lovastatin
PAD
IC

Additional relevant MeSH terms:
Intermittent Claudication
Vascular Diseases
Peripheral Vascular Diseases
Peripheral Arterial Disease
Arteriosclerosis
Arterial Occlusive Diseases
Cardiovascular Diseases
Signs and Symptoms
Atherosclerosis
Niacin
Lovastatin
Nicotinic Acids
Niacinamide
Vasodilator Agents
Cardiovascular Agents
 Therapeutic Uses
Pharmacologic Actions
Hypolipidemic Agents
Antimetabolites
Molecular Mechanisms of Pharmacological Action
Lipid Regulating Agents
Vitamin B Complex
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Hydroxymethylglutaryl-CoA Reductase Inhibitors
Anticholesteremic Agents
Enzyme Inhibitors

ClinicalTrials.gov processed this record on May 19, 2013